Andera has co-led the company\u2019s $118 million Series B financing in June 2022 and re-invested into the oversubscribed IPO financing.<\/p>\n
Mineralys is a US based clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has completed a Phase 2 study in uncontrolled and resistant hypertension and has announced positive results in November 2022. The IPO financing will support the company to advance its pivotal program in uncontrolled hypertension in the United States.<\/p>\n
Through this IPO on Nasdaq, Andera Partners supported again the growth of its portfolio companies through public market financing. The importance of such growth path has also been exemplified by Andera\u2019s ex-portfolio company, Axonics Modulation Technologies which was listed on Nasdaq in 2018 and has grown to a multi-billion dollar medical device leader on the back of solid execution and strong interest of public investors. Andera realized full exit of Axonics in 2022.<\/p>\n
<\/p>\n